PreveCeutical Medical Inc. (PRVCF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.95 Million CAD | 23.54% |
| 2022 | 4.82 Million CAD | 13.11% |
| 2021 | 4.26 Million CAD | 9.19% |
| 2020 | 3.9 Million CAD | -26.91% |
| 2019 | 5.34 Million CAD | 27.64% |
| 2018 | 4.18 Million CAD | 42.23% |
| 2017 | 2.94 Million CAD | 485.0% |
| 2016 | 503.24 Thousand CAD | 417.7% |
| 2015 | 97.2 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 6.19 Million CAD | 4.0% |
| 2024 Q2 | 6.46 Million CAD | 4.25% |
| 2023 Q3 | 5.6 Million CAD | 4.75% |
| 2023 Q1 | 5.1 Million CAD | 5.82% |
| 2023 Q4 | 5.95 Million CAD | 6.32% |
| 2023 Q2 | 5.35 Million CAD | 4.82% |
| 2023 FY | 5.95 Million CAD | 23.54% |
| 2022 Q1 | 4.25 Million CAD | -0.17% |
| 2022 FY | 4.82 Million CAD | 13.11% |
| 2022 Q3 | 4.67 Million CAD | 4.34% |
| 2022 Q2 | 4.47 Million CAD | 5.15% |
| 2022 Q4 | 4.82 Million CAD | 3.27% |
| 2021 Q3 | 3.94 Million CAD | 3.35% |
| 2021 FY | 4.26 Million CAD | 9.19% |
| 2021 Q2 | 3.81 Million CAD | 7.47% |
| 2021 Q1 | 3.54 Million CAD | -9.19% |
| 2021 Q4 | 4.26 Million CAD | 8.25% |
| 2020 Q4 | 3.9 Million CAD | 10.96% |
| 2020 Q2 | 3.84 Million CAD | -29.56% |
| 2020 FY | 3.9 Million CAD | -26.91% |
| 2020 Q1 | 5.46 Million CAD | 2.24% |
| 2020 Q3 | 3.52 Million CAD | -8.52% |
| 2019 FY | 5.34 Million CAD | 27.64% |
| 2019 Q4 | 5.34 Million CAD | -15.34% |
| 2019 Q3 | 6.31 Million CAD | 2.97% |
| 2019 Q1 | 5.28 Million CAD | 26.24% |
| 2019 Q2 | 6.13 Million CAD | 15.98% |
| 2018 Q3 | 3.6 Million CAD | -14.99% |
| 2018 FY | 4.18 Million CAD | 42.23% |
| 2018 Q4 | 4.18 Million CAD | 16.19% |
| 2018 Q2 | 4.23 Million CAD | 10.34% |
| 2018 Q1 | 3.84 Million CAD | 30.49% |
| 2017 Q2 | 2.73 Million CAD | 3313.13% |
| 2017 Q4 | 2.94 Million CAD | 13.86% |
| 2017 FY | 2.94 Million CAD | 485.0% |
| 2017 Q1 | 80.12 Thousand CAD | 353.26% |
| 2017 Q3 | 2.58 Million CAD | -5.46% |
| 2016 Q3 | 57.91 Thousand CAD | 454.82% |
| 2016 Q2 | 10.43 Thousand CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | 503.24 Thousand CAD | 417.7% |
| 2016 Q4 | 17.67 Thousand CAD | -69.48% |
| 2015 FY | 97.2 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 91.776% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 37.041% |
| CSL Limited | 18.62 Billion USD | 99.968% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 89.901% |
| Regen BioPharma, Inc. | 5.45 Million USD | -9.199% |
| BioStem Technologies, Inc. | 15.9 Million USD | 62.529% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 88.143% |
| Qrons Inc. | 1.48 Million USD | -300.324% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -636.86% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.045% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 67.616% |
| Skye Bioscience, Inc. | 14.07 Million USD | 57.649% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -13233.811% |
| Rebus Holdings, Inc. | 5.24 Million USD | -13.691% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2863.305% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -21624.492% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.551% |
| Neon Bloom, Inc. | 1.22 Million USD | -386.023% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 88.82% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 37.804% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1313.694% |
| SQZ Biotechnologies Company | 50.03 Million USD | 88.09% |
| Intellipharmaceutics International Inc. | 12 Million USD | 50.372% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -54.74% |
| Mesoblast Limited | 188.44 Million USD | 96.837% |
| Marizyme, Inc. | 26.67 Million USD | 77.659% |
| Genus plc | 485 Million USD | 98.771% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -2.004% |
| Pharming Group N.V. | 244.07 Million USD | 97.558% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -196.482% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -136.84% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -56.834% |
| ContraFect Corporation | 32.53 Million USD | 81.68% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -200.795% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -55.701% |
| IMV Inc. | 37.93 Million USD | 84.289% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 49.401% |
| MultiCell Technologies, Inc. | 1617.67 USD | -368311.357% |
| ONE Bio Corp. | 27.49 Million USD | 78.325% |
| Accustem Sciences Inc. | 1.07 Million USD | -452.211% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.302% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -181.772% |
| Q BioMed Inc. | 8.13 Million USD | 26.722% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 92.814% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -15.811% |
| Biomind Labs Inc. | 1.49 Million USD | -297.68% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 94.98% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 34.09% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -315.639% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4094.152% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -3.722% |
| GB Sciences, Inc. | 5.41 Million USD | -10.007% |
| Alpha Cognition Inc. | 7.16 Million USD | 16.82% |
| HST Global, Inc. | 593.59 Thousand USD | -904.001% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -373.294% |
| Halberd Corporation | 728.71 Thousand USD | -717.83% |
| Enzolytics Inc. | 365.26 Million USD | 98.368% |
| Agentix Corp. | 2.51 Million USD | -137.385% |
| Resverlogix Corp. | 67.39 Million USD | 91.157% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -610.558% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.661% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -247.706% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 75.917% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 49.932% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -62.603% |
| AVAX Technologies, Inc. | 3.99 Million USD | -49.225% |
| Zenith Capital Corp. | 27.56 Thousand USD | -21517.324% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2397.205% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -59.593% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -775.35% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -119.781% |
| Kadimastem Ltd | 3.5 Million USD | -70.04% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8804.481% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1182.482% |
| LadRx Corporation | 2.2 Million USD | -170.83% |
| Cell Source, Inc. | 15.8 Million USD | 62.297% |
| Regen BioPharma, Inc. | 5.45 Million USD | -9.199% |
| NovAccess Global Inc. | 7.86 Million USD | 24.184% |
| Affymax, Inc. | 8.87 Million USD | 32.818% |
| Itoco Inc. | 1.65 Million USD | -260.504% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -190.494% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 1.477% |
| Mobile Lads Corp. | 1.31 Million USD | -353.726% |
| CytoDyn Inc. | 127.89 Million USD | 95.34% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -14157.949% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -280.475% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 46.043% |
| SYBLEU INC | 681.41 Thousand USD | -774.606% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 2.331% |
| International Stem Cell Corporation | 5.27 Million USD | -12.937% |
| Bioxytran, Inc. | 3.24 Million USD | -83.403% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -852.316% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -29.078% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 85.463% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 73.233% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -194.249% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -8.793% |
| Neutra Corp. | 973.52 Thousand USD | -512.173% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 79.46% |
| PureTech Health plc | 125.58 Million USD | 95.254% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -58.623% |
| IXICO plc | 1.9 Million USD | -213.619% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 70.969% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.232% |
| CSL Limited | 18.62 Billion USD | 99.968% |
| Cellectis S.A. | 249.36 Million USD | 97.61% |